Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
UTD2 is the world's first oral epothilone microtubule inhibitor
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated
